Sangamo Therapeutics Retains Raymond James to Explore Strategic Alternatives

Sangamo Therapeutics has retained Raymond James as its financial advisor to evaluate a full range of strategic alternatives intended to advance its pipeline and maximize value for all stakeholders. The genomic medicine company, trading on the OTCQB Venture Market under the ticker SGMO, announced the strategic review on June 8, 2026, from its headquarters in Richmond, California.

"With our best-in-class BLA-ready Fabry gene therapy program, differentiated zinc finger epigenetic regulation and capsid delivery platforms, and innovative MINT platform for large-scale genomic engineering, we have made the decision to explore alternatives to continue advancing these important assets to patients in need," said the company's Chief Executive Officer.

The company's lead asset is isaralgagene civaparvovec (ST-920), a one-time gene therapy for Fabry disease. The registrational Phase 1/2 STAAR study evaluating the therapy is complete, with 32 patients transitioned to long-term follow-up. The rolling submission of a Biologics License Application to the FDA has been initiated under the Accelerated Approval pathway, with the first two modules submitted. The FDA has recently affirmed that two-year eGFR data may serve as confirmatory evidence for traditional approval.

ST-920 holds multiple regulatory designations, including Orphan Drug, Fast Track, and RMAT from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency, and Innovative Licensing and Access Pathway from the UK's MHRA.

Sangamo's pipeline also includes ST-503, an epigenetic regulator for chronic neuropathic pain due to small fiber neuropathy, which has FDA Fast Track designation. Seven sites are activated for the Phase 1/2 STAND study. Additionally, clinical trial application enabling activities are in progress for ST-506, an epigenetic regulator for prion disease leveraging the company's proprietary neurotropic AAV capsid, STAC-BBB.

The STAC-BBB capsid delivery platform is licensed to Genentech, Astellas, and Eli Lilly, generating $88 million in license fees to date and carrying up to $4.6 billion in potential future milestones and exercise fees. The company's intellectual property portfolio includes 834 patents and applications across 90 families.

The company noted that no transaction agreement has been reached, and there is no set timetable or assurance that any deal will occur. Parties interested in discussing potential transactions were directed to contact the company's business development team.